Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT06772168

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
CMG Pharmaceutical Co. Ltd (from the registry)
Registry
  • NCT NCT06772168
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06772168. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-19 (actual); primary completion 2026-11-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Condition
Dyslipidemia
Intervention (Drug)
CMG190303(Dapagliflozin/Rosuvastatin)
Intervention (Drug)
Comparator 1: Dapagliflozin/Rosuvastatin placebo
Intervention (Drug)
Rosuvastatin/Dapagliflozin placebo
Lead sponsor
CMG Pharmaceutical Co. Ltd (class: industry)

Record details

Record id
cardio:ct-nct06772168
Content hash
3ca5675b8d938d7a79146c02414a207caf5726fbe0eb12649c643832ad706801